News:
Clinical trials
news & eventsClinical trials are experiments or observations done in clinical research, designed to answer specific questions about biomedical or behavioural interventions, including new treatments (vaccines, drugs, dietary choices, dietary supplements, and medical devices etc.) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought.
Source: Wikipedia
Clinical trials news:
Participate in online survey
Do you have diffuse scleroderma? Your help is needed in this survey.
FDA grants Fast Track designation to nintedanib
FESCA is very happy to share the news, that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease. (SSc-ILD).
Phase 2 clinical study for patients with dcSSc or PAH
The American company, Cumberland Pharmaceuticals, is conducting a phase 2 clinical study evaluating the safety and effectiveness of a new oral drug product.
Orphan Drug Designation Granted to Nintedanib
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Efficacy and Safety of Tocilizumab
Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (Clinical trial)
Scleroderma research
FESCA, Federation of European Scleroderma Associations aisbl, encourages and undertake surveys, research projects and clinical trials related to the systemic sclerosis disease, and the publication of the results of any such research.
FESCA is always looking for better therapies. This is why we are partners with many different pharma companies. Pay our Scleroderma projects section a visit, and learn more about scleroderma research projects we're involved in.